The osteoclast cytoskeleton - current understanding and therapeutic perspectives for osteoporosis

J Cell Sci. 2020 Jul 1;133(13):jcs244798. doi: 10.1242/jcs.244798.

Abstract

Osteoclasts are giant multinucleated myeloid cells specialized for bone resorption, which is essential for the preservation of bone health throughout life. The activity of osteoclasts relies on the typical organization of osteoclast cytoskeleton components into a highly complex structure comprising actin, microtubules and other cytoskeletal proteins that constitutes the backbone of the bone resorption apparatus. The development of methods to differentiate osteoclasts in culture and manipulate them genetically, as well as improvements in cell imaging technologies, has shed light onto the molecular mechanisms that control the structure and dynamics of the osteoclast cytoskeleton, and thus the mechanism of bone resorption. Although essential for normal bone physiology, abnormal osteoclast activity can cause bone defects, in particular their hyper-activation is commonly associated with many pathologies, hormonal imbalance and medical treatments. Increased bone degradation by osteoclasts provokes progressive bone loss, leading to osteoporosis, with the resulting bone frailty leading to fractures, loss of autonomy and premature death. In this context, the osteoclast cytoskeleton has recently proven to be a relevant therapeutic target for controlling pathological bone resorption levels. Here, we review the present knowledge on the regulatory mechanisms of the osteoclast cytoskeleton that control their bone resorption activity in normal and pathological conditions.

Keywords: Intermediate filament; Microtubule; Osteoclast; Osteoporosis; Rho GTPase; Septin.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Bone Resorption* / drug therapy
  • Bone Resorption* / genetics
  • Cell Differentiation
  • Cytoskeleton
  • Humans
  • Microtubules
  • Osteoclasts
  • Osteoporosis* / drug therapy